Skip to main content

Withdrawing of the licence for the use of dapagloflozin in Type 1 diabetes

ABCD is keen to ensure that all our members are aware of the withdrawing of the licence for the use of dapagloflozin in Type 1 diabetes .
Apologies if you've had this update from multiple sources.
We are currently collating feedback on this decision from experts in this area, to share with ABCD members to ensure that people with Type 1 diabetes get the best care and can make informed decisions. 
 

File(s)